July 19, 2012,Lincoln, NE: LI-COR Biosciences recently signed a non-exclusive license with Cambridge Research Biochemicals (CRB) to develop, manufacture, and sell IRDye® QC-1 and IRDye near-infrared dye-labeled peptides for research use only. This partnership will allow CRB to provide dye-labeled peptides to its customers, a unique product in the field of fluorescence imaging applications.
"We are very excited that CRB now offers our IRDye near-infrared dye technologies," says Jim Wiley, LI-COR senior strategic marketing manager. "The expertise and quality for custom peptide synthesis from CRB, coupled with LI-COR dye technologies, will allow our customers to create innovative solutions for their research needs."
LI-COR offers infrared fluorescent dyes that can be conjugated to peptides, proteins, and antibodies for applications with detection in the 650 - 800nm range. IRDye QC-1 is the only nonfluorescent quencher available that is compatible with a wide range of visible and near-infrared fluorophores (~500 nm - 800 nm).
"We provide the best variety of available dyes to customers who have the need to expand their choices as research techniques become more sophisticated," says Emily Humphrys, CRB commercial director. "In vivo fluorescence imaging, for example, requires using the long wavelength dyes that LI-COR provides. This partnership will keep CRB at the forefront of the dye-labeled market."
To learn more about IRDye QC-1 and other IRDye infrared dye products, please visit www.licor.com/bio or contact email@example.com. To request a dye-labeled product, visit CRB's quotation request form or contact firstname.lastname@example.org.
Cambridge Research Biochemicals (CRB) was established in 1980. Its core business is the chemical synthesis of peptides and the custom production of polyclonal antibodies. The company has a global market-base, drawing customers from many research sectors, including pharmaceutical, academia and biotech. All CRB products are for research purposes only and are used as custom reagents for proof of principle studies within early phase drug discovery and to support biomarker programs in clinical studies.